Down-regulation of HtrA1 activates the Epithelial-Mesenchymal transition and ATM DNA damage response pathways

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Wang, Ning ^a   Eckert, Kristin A ^a   Zomorrodi, Ali R ^b   Xin, Ping ^a   Pan, Weihua ^a   Shearer, Debra A ^a   Weisz, Judith ^a   Maranus, Costas D ^b   Clawson, Gary A ^a,c  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b The Pennsylvania State University   (United States)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; HTRA1 PROTEIN; MICRORNA 200; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER INVASION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; GROWTH RATE; HTRA1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; NUCLEOTIDE SEQUENCE;

BREAST NEOPLASMS; CELL LINE, TUMOR; DNA DAMAGE; DOWN-REGULATION; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; SERINE ENDOPEPTIDASES;

EID: 84862751215     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039446     Document Type: Article

References (89)

1. Zumbrunn J, Trueb B, (1996) Primary structure of a putative serine protease specific for IGF-binding proteins. FEBS Lett 398: 187-192.
2. Clawson GA, Bui V, Xin P, Wang N, Pan W, (2008) Intracellular localization of the tumor suppressor HtrA1/Prss11 and its association with HPV16 E6 and E7 proteins. J Cellular Biochem 105: 81-88.
3. De Luca A, De Falco M, Severino A, Campioni M, Santini D, et al. (2003) Distribution of the serine protease HtrA1 in normal human tissues. J Histochem Cytochem 51: 1279-1284.
4. Yang Z, Camp N, Sun H, Tong Z, Gibbs D, et al. (2006) A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science 314: 992-993.
5. Fukutake T, (2011) Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL): from discovery to gene identification. J Stroke Cerebrovasc Dis 20: 85-93.
6. Chien J, Staub J, Hu S, Erickson-Johnson M, Couch F, et al. (2004) A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. Oncogene 23: 1636-1644.
7. Mullany SA, Moslemi-Kebria M, Rattan R, Khurana A, Clayton A, et al. (2011) Expression and functional significance of HtrA1 loss in endometrial cancer. Clin Cancer Res 17: 427-436.
8. Zhu F, Jin L, Luo TP, Luo GH, Tan Y, et al. (2010) Serine protease HtrA1 expression in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 9: 508-512.
9. Baldi A, Mottolese M, Vincenzi B, Campioni M, Mellone P, et al. (2008) The serine protease HtrA1 is a novel prognostic factor for human mesothelioma. Pharmacogenomics 9: 1069-1077.
10. Baldi A, De Luca A, Morini M, Battista T, Felsani A, et al. (2002) The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells. Oncogene 21: 6684-6688.
11. Chien J, Aletti G, Baldi A, Catalano V, Muretto P, et al. (2006) Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest 116: 1994-2004.
12. Chien J, Campioni M, Shridhar V, Baldi A, (2009) HtrA serine proteases as potential therapeutic targets in cancer. Curr Cancer Drug Targets 9: 451-468.
13. Zurawa-Janicka D, Skorko-Glonek J, Lipinska B, (2010) HtrA proteins as targets in therapy of cancer and other diseases. Expert Opin Ther Targets 14: 665-679.
14. Narkiewicz J, Klasa-Mazurkiewicz D, Zurawa-Janicka D, Skorko-Glonek J, Emerich J, et al. (2008) Changes in mRNA and protein levels of human HtrA1, HtrA2, and HtrA3 in ovarian cancer. Clin Biochem 41: 561-569.
15. Zurawa-Janicka D, Kobiela J, Stefaniak T, Wozniak A, Narkiewicz J, et al. (2008) Changes in expression of serin eproteases HtrA1 and HtrA2 during estrogen-induced oxidative strress and nephrocarcinogenesis in male Syrian hamster. Acta Biochim Pol 55: 9-19.
16. Narkiewicz J, Lapinski-Szumczyk S, Jurawa-Janicka D, Skorko-Glonek J, Emerich J, et al. (2009) Expression of human HtrA1, HtrA2, HtrA3, and TGF-beta1 genes in primary endometrial cancer. Oncol Rpt 21: 1529-1537.
17. Bowden M, Di Nezza-Cossens L, Jobling T, Salamonsen L, Nie G, (2006) Serine protease HTRA1 and HTRA3 are down-regualted with increasing grades of human endometrial cancer. Gynecol Oncol 103: 253-260.
18. Catalona V, Pasquale M, d-Avino A, Shridhar V, Staccioli MP, et al. (2011) HtrA1, a potential predictor of response to cisplatin-based combination chemotherapy in gastric cancer. Histopathology 58: 669-678.
19. Folgueira M, Carraro D, Brentani H, Patrao D, Barbosa E, et al. (2005) Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 11: 7434-7443.
20. He X, Ota T, Liu P, Chien J, Shridhar V, (2010) Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells. Cancer Res 70: ePub Apr 13.
21. Chien J, Ota T, Aletti G, Shridhar R, Boccellino M, et al. (2009) Serine protease HtrA1 associates with microtubules and inhibits cell migration. Mol Cell Biol 29: 4177-4187.
22. Chien J, He X, Shridhar V, (2009) Identification of tubulins as substrates of serine protease HtrA1 by mixture-based oriented peptide library screening. J Cell Biochem 107: 253-263.
23. Strnad P, Stumptner C, Zatloukal K, Denk H, (2008) Intermediate filament cytoskeleton of the liver in health and disease. Histochem Cell Biol 129: 735-749.
24. Rogers KR, Morris CJ, Blake DR, (1989) Cytoskeletal rearrangement by oxidative stress. Int J Tissue React 11: 309-314.
25. Wang Z, Li Y, Sarkar FH, (2010) Signaling mechanism(s) of reactive oxygen species in Epithelial-Mesenchymal Transition reminiscent of cancer stem cells in tumor progression. Curr Stem Cell Res Ther 5: 74-80.
26. Ahmed N, Abubaker K, Findlay J, Quinn M, (2010) Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets 10: 268-278.
27. Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, et al. (2010) Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat 13: 109-118.
28. Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, et al. (2010) Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 101: 293-299.
29. Voulgari A, Pintzas A, (2009) Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 1796: 75-90.
30. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, et al. (2006) Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66: 944-950.
31. Singh A, Settleman J, (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751.
32. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, et al. (2008) The iR-200 family and miR-205 regulate epithelial to mesenchymal transition by argeting ZEB1 and SIP1/. Nature Cell Biol 10: 593-601.
33. Iliopoulos D, Polytarchou C, Hatziapostolou M, Kottakis F, Maroulakou IG, et al. (2009) MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci Signal 2: ra62.
34. Polyak K, Weinberg RA, (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273.
35. Weisz J, Shearer DA, Murata E, Patrick SD, Han B, et al. (2012) Identification of mammary epithelial cells subject to chronic oxidative stress in mammary epithelium of young women and teenagers living in USA. Cancer Biol Therapy 13: 1-13.
36. Zupkovitz G, Tischler J, Posch M, Sadzak I, Ramsauer K, et al. (2006) Negative and positive regulation of gene expression by mouse histone deacetylase 1. Mol Cell Biol 26: 7913-7928.
37. Pan W, Xin P, Clawson GA, (2010) MicroRNAs align with accessible sites in target mRNAs. J Cell Biochem 109: 509-518.
38. Fillmore CM, Kuperwasser C, (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypiclly diverse progeny and survive chemotherapy. Breast Can Res 10: R25.
39. Liu Y, (2004) Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 15: 1-12.
40. Holian J, Qi W, Kelly DJ, Zhang Y, Mreich E, et al. (2008) Role of Kruppel-like factor 6 in transforming growth factor-beta1-induced epithelial-mesenchymal transition of proximal tubule cells. Am J Physiol Renal Physiol 295: F1388-1396.
41. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004) Identification of human brain tumour initiating cells. Nature 432: 396-401.
42. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF, (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988.
43. Hubbi ME, Luo W, Baek JH, Semenza GL, (2011) MCM proteins are negative regulators of hypoxia-inducible factor 1. Mol Cell 42: 700-712.
44. Cicenas J, (2008) The potential role of AKT phosphorylation in human cancers. Int J Biol Markers 23: 1-9.
45. Yang SX, Costantino JP, Kim C, Mamounas EP, Nguyen D, et al. (2010) AKT phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positivebreast cancer. J Clin Oncol 28: 2974-2981.
46. Rogakou EP, Boon C, Redon C, Bonner WM, (1999) Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 146: 905-916.
47. Tang JT, Wang JL, Du W, Hong J, Zhao SL, et al. (2011) MicroRNA 345, a methylation-sensitive microRNA is involved in cell proliferation and invasion in human colorectal cancer. Carcinogenesis 32: 1207-1215.
48. Ye G, Fu G, Cui S, Zhao S, Bernaudo S, et al. (2011) MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J Cell Sci 124: 359-368.
49. Lopez JA, Alvarez-Salas LM, (2011) Differential effects of miR-34c-3p and miR-34c-5p on SiHa cells proliferation, apoptosis, migration and invasion. Biochem Biophys Res Commun 409: 513-519.
50. Hagman Z, Larne O, Edsjo A, Bjartell A, Ehrnstrom RA, et al. (2010) miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer 127: 2768-2776.
51. Stinson S, Lackner MR, Adai AT, Yu N, Kim H-J, et al. (2011) TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Science Signaling 4: 1-11.
52. Loss LA, Sadanandam A, Durinck S, Nautival S, Flaucher D, et al. (2010) Prediction of epigenetically regulated genes in breast cancer cell lines. BMC Bioinformatics 11: 305.
53. Turk B, (2006) Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 5: 785-799.
54. Radisky D, Bissell M, (2006) Matrix metalloproteinase-induced genomic instability. Curr Opin Genet Dev 16: 45-50.
55. Coussens LM, Fingleton B, Matrisian LM, (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392.
56. Overall CM, Lopez-Otin C, (2002) Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2: 657-672.
57. Lopez-Otin C, Matrisian LM, (2007) Emerging roles of proteases in tumour suppression. Nat Rev Cancer 7: 800-808.
58. Thiery JP, (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15: 740-746.
59. Dvorak HF, (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315: 1650-1659.
60. Yoo YG, Christensen J, Gu J, Huang LE, (2011) HIF-1(alpha) mediates tumor hypoxia to confer a perpetual mesenchymal phenotype for malignant progression. Sci Signal 21: pt4.
61. Yoo YG, Christensen J, Huang LE, (2011) HIF-1a confers aggressive malignant traits on human tumor cells independent of its canonical transcription function. Cancer Res 71: 1244-1252.
62. Kimbro KS, Simons JW, (2006) Hypoxia-inducible factor-1 in human breast and prostate cancer. Endoc Relat Cancer 13: 739-749.
63. Axelson H, Fredlund E, Overberger M, Landberg G, Pahlman S, (2005) Hypoxia-induced dedifferentiation of tumor cells - a mechanisms behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol 16: 554-563.
64. Van den Eynden GG, Van Laere SJ, Van der Auwera I, Gilles L, Burn JL, et al. (2007) Differential expression of hypoxia and (lymph)angiogenesis-related genes at different metastatic sites in breast cancer. Clin Exp Metastasis 24: 13-23.
65. Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, et al. (2010) Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 8: 1207-1216.
66. Vrba L, Jensen TJ, Garbe JC, Heimark RL, Cress AE, et al. (2010) Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS One 13: e8697.
67. Davalos V, Moutinho C, Villanueva A, Boque R, Silva P, et al. (2011) Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene doi:10.1038/onc.2011.383 Epub ahead of print.
68. Moreno-Bueno G, Portillo F, Cano A, (2008) Transcriptional regulation of cell polarity in EMT and cancer. Oncogene 27: 6958-6969.
69. Biswas S, Criswell TL, Wang SE, Arteaga CL, (2006) Inhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy. Clin Cancer Res 12: 4142-4146.
70. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, et al. (2000) An elevated serum level of transforming growth factor-beta 1 (TGF-beta 1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma. Anticancer Res 20: 4489-4493.
71. Shariat SF, Kim JH, Andrews B, Kattan MW, Wheeler TM, et al. (2001) Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer 92: 2985-2992.
72. Ivanovic V, Demajo M, Krtolica K, Krajnovic M, Konstantinovic M, et al. (2006) Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients. Clin Chim Acta 371: 191-193.
73. Oka C, Tsujimoto R, Kajikawa M, Koshiba-Takeuchi K, Ina J, et al. (2004) HtrA1 serine protease inhibits signaling mediated by tgf-beta family proteins. Development 131: 1041-1053.
74. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M, (2006) Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160: 1-40.
75. Klaunig JE, Kamendulis LM, Hocevar BA, (2010) Oxidative stress and oxidative damage in carcinogenesis. Toxicol Pathol 38: 96-109.
76. Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT, (2010) ATM activation by oxidative stress. Science 330: 517-521.
77. Polo SE, Jackson SP, (2011) Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. Genes Dev 25: 409-433.
78. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, Hurov KE, et al. (2007) ATM and ATR substrate analysis reveals extensive protein networks reponsive to DNA damage. Science 316: 1160-1166.
79. Shiloh Y, (2006) The ATM-mediated DNA-damage reponse: taking shape. Trend Biochem Sci 31: 402-410.
80. Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, et al. (2008) Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 68: 605-614.
81. Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, et al. (2002) Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 234-235: 119-124.
82. Kotamraju S, Kalivendi SV, Konorev E, Chitambar CR, Joseph J, et al. (2004) Oxidant-induced iron signaling in Doxorubicin-mediated apoptosis. Methods Enzymol 378: 362-382.
83. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, et al. (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci 106: 13820-13825.
84. Pan WH, Clawson GA, (2006) Identifying accessible sites in RNA: the first step in designing antisense reagents. Curr Med Chem 13: 3083-3103.
85. Pan W, Xin P, Morrey J, Clawson G, (2004) A Self-Processing Ribozyme Cassette: Utility against Human Papillomavirus 11 E6/E7 mRNA and Hepatitis B virus. Mol Therapy 9: 596-606.
86. Benjamini Y, Hochbert Y, (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Royal Statistical Soc, Serie B (Methodological) 57: 289-300.
87. Benjamini Y, Yekutieli D, (2001) The control of the false discovery rate in multiple testing under dependency. Annals Statistics 29: 1165-1188.
88. Abdi H, (2007) Bonferroni and Sidak corrections for multiple comparisons. In: Salkind NJ, editors. editor. Encyclopedia of Measurement and Statistics. Thousand Oaks, CA: Sage.
89. Kaufman L, Rousseauw PJ, (1990) Finding groups in data. An introduction to cluster analysis. New York, New York: Wiley.